Myrobalan Therapeutics Completes Series A Financing Of $24 Million To Develop Potentially First-In-Class Cns Therapeutics With Restorative Potential
Round Type
Series A
MedfordBiotechnologyInvestors
Description
Myrobalan Therapeutics, a biotechnology company developing novel oral neurorestorative therapies to repair damage and restore neural function in high-unmet need degenerative CNS conditions, today announced completion of a $24 million Series A funding. Funding was led by Co-win Ventures, with participation from new and existing investors including, Guan Zi Equity Investment (Li Shui) Partnership (Limited Partnership), 3E Bioventures Capital, and AB Magnitude Ventures Group.
Quick answer
Myrobalan Therapeutics raised an undisclosed amount in a Series A round, dated January 10, 2024. Investors: AB Magnitude Ventures Group, 3 E Bioventures Capital, Guan Zi Equity Investment Partnership and Co Win Ventures. Myrobalan Therapeutics is based in Medford, Massachusetts, United States.
- How much did Myrobalan Therapeutics raise?
- Myrobalan Therapeutics raised an undisclosed amount in a Series A round on January 10, 2024.
- Who invested in Myrobalan Therapeutics?
- AB Magnitude Ventures Group, 3 E Bioventures Capital, Guan Zi Equity Investment Partnership and Co Win Ventures are named as investors in this round.
- What does Myrobalan Therapeutics do?
- Myrobalan Therapeutics is a preclinical stage biotechnology company headquartered in Medford, Massachusetts, with a focus on developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain..
- Where is Myrobalan Therapeutics based and how big is it?
- Myrobalan Therapeutics is based in Medford, Massachusetts, United States. Fundz records about 21 employees.
- Who are the decision-makers at Myrobalan Therapeutics?
- Fundz holds 2 contacts at Myrobalan Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Myrobalan Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- DeepLook Medical raised $1.7M (Seed) on February 23, 2024.
- Lumicell raised $2.3M (Seed) on February 22, 2024.
- Simple Planet raised $6M (Series A) on February 22, 2024.
- Frontier Medicines Corp raised $80M (Series C) on February 22, 2024.
- Samphire Neuroscience raised $2.3M (Pre-Seed) on February 21, 2024.
- INSAMO raised $12M (Seed) on February 21, 2024.
Who to call at Myrobalan Therapeutics, and when
A new round usually means Myrobalan Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Myrobalan Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Myrobalan Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Myrobalan Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Myrobalan Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansMyrobalan Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.